

Q² 1 (Amended). A method for treating or preventing pathophysiological consequences of mitochondrial respiratory chain dysfunction in a mammal comprising administering to said mammal in need of such treatment or prevention an effective amount of a pyrimidine nucleotide precursor, thereby treating or preventing said consequences; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

Q³ 32 (Amended). A method for preventing death or functional decline of post-mitotic cells in a mammal due to mitochondrial respiratory chain dysfunction comprising administration of an effective amount of a pyrimidine nucleotide precursor, thereby preventing said death or functional decline; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

Q⁴ 36 (Amended). A method for treating developmental delay in cognitive, motor, language, executive function, or social skills in a mammal comprising administration of an effective amount of a pyrimidine nucleotide precursor, thereby treating said developmental delay; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

Q⁵ 41. A method for reducing side effects of cytotoxic cancer chemotherapy agents by administering a pyrimidine nucleotide precursor, where said cytotoxic

chemotherapy agent is not a pyrimidine nucleoside analog, thereby reducing said
side-effects; wherein said effective amount is from 0.05 to 0.3 grams of said
precursor per kilogram body weight per day.

0903135 042001
FO0240 9ET8860